Full Schedule

2:00 PM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

4:00 PM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:30 AM – 6:00 PM ADT

Lactation Room

Location: MR505

7:30 AM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:30 AM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

8:30 AM – 12:30 PM ADT

Introduction to Drug Utilization Research: The Conduct of Real-World Drug Utilization Studies: Describe and Compare

Location: MR106/107

Lead Speaker: – University Medical Center Groningen

Lead Speaker: – Syddansk Universitet

Speaker: – University of Toronto

Speaker: – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

Speaker: – Uppsala university

8:30 AM – 12:30 PM ADT

Pharmacoepidemiologist's Toolbox for Professional Empowerment

Location: Argyle 1

Moderator: – University of North Carolina at Chapel Hill

Moderator: – Regeneron Pharmaceuticals, Inc.

Speaker: – Perelman School of Medicine at the University of Pennsylvania

Speaker: – Food and Drug Administration

Speaker: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

8:30 AM – 12:30 PM ADT

Pharmacogenomics & Precision Medicine for Pharmacoepidemiologists

Location: MR201

Lead Speaker:

Lead Speaker: – University of Missouri School of Medicine

Speaker: – University of Florida

Speaker: – Amsterdam UMC

Speaker: – University of British Columbia

8:30 AM – 12:30 PM ADT

Practical Skills In Protocol Writing and Statistical Analytic Programming Relevant to Studies Generating Real-World Evidence (RWE)

Location: MR202

Lead Speaker: – U.S. Food and Drug Administration

Speaker: – Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Speaker: – Regeneron

Speaker: – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Speaker: – UNSW Sydney

Speaker: – US Food and Drug Administration

Speaker:

8:30 AM – 12:30 PM ADT

Principles of Pharmacoepidemiology

Location: Argyle 2

Lead Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Speaker: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: – Leibniz Institute for Prevention Research and Epidemiology - BIPS

8:30 AM – 12:30 PM ADT

Regulatory Pharmacoepidemiology

Location: MR501/502

Lead Speaker: – FDA/CDRH/ Office of Clinical Evidence and Analysis

Speaker: – Medicines and Healthcare products Regulatory Agency

8:30 AM – 12:30 PM ADT

Using Pharmacoepidemiology Database Resources to Address Drug Safety Research

Location: Argyle 3

Lead Speaker: – Janssen Pharmaceuticals

Speaker: – ARS Toscana, Florence, Italy

Speaker: – Flatiron Health

Speaker: – Carelon Research

Speaker: – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC

12:30 PM – 2:00 PM ADT

Lunch on Your Own

1:00 PM – 5:00 PM ADT

ISPE Board of Directors' Meeting

Location: MR604

2:00 PM – 6:00 PM ADT

Cancer Pharmacoepidemiology and Genomics: What You Should Know in the Era of Precision Medicine

Location: MR501/502

Lead Speaker: – DHHS/NIH/NICHD

Lead Speaker: – University of British Columbia

Speaker: – Oncology Center of Excellence, US Food and Drug Administration

Speaker: – Eli Lilly and Company

Speaker: – Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

2:00 PM – 6:00 PM ADT

Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounder

Location: Argyle 1

Lead Speaker: – UNC Chapel Hill Gillings School of Global Public Health

Speaker: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Speaker: – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC

Speaker: – Pfizer

Speaker: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Speaker: – Karolinska Institutet

2:00 PM – 6:00 PM ADT

Methods and New Approaches in Pragmatic Trials

Location: MR201

Lead Speaker: – TargetRWE

Lead Speaker: – Merck

Speaker: – CERobs Consulting, LLC

Speaker: – Patient Centered Outcomes Research Institute

Speaker: – Core Clinical Sciences

Speaker: – Target RWE

2:00 PM – 6:00 PM ADT

Pediatric Pharmacoepidemiology: Adapting Pharmacoepidemiologic Principles to Studies of the Pediatric Population

Location: MR106/107

Lead Speaker: – Pfizer, Inc.

Speaker: – US FDA

Speaker: – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA

Speaker: – Merck & Co., Inc., Rahway, NJ, United States

Speaker: – Office of Pediatric Therapeutics

2:00 PM – 6:00 PM ADT

Propensity Scores in Pharmacoepidemiology

Location: Argyle 2

Lead Speaker: – Optum Epidemiology

Speaker: – Aetion

2:00 PM – 6:00 PM ADT

Real-World Evidence (RWE) Generation for Rare Disease Drug Development and Orphan Drug Approvals

Location: MR605

Lead Speaker: – IQVIA

Speaker: – Janssen R&D, LLC

Speaker: – RTI Health Solutions

Speaker: – US Food and Drug Administration

2:00 PM – 6:00 PM ADT

Using Field Studies to Value-Add in Pharmacoepidemiology

Location: MR202

Lead Speaker: – University of Groningen

Speaker: – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

Speaker: – College of Pharmacy, Dalhousie University

2:00 PM – 6:00 PM ADT

Weighting the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development

Location: Argyle 3

Lead Speaker: – RTI Health Solutions

Speaker: – Takeda

Speaker: – Epidemiology & Benefit - Risk Evaluation, Sanofi

Speaker: – Janssen Pharmaceuticals

Speaker: – RTI Health Solutions

7:30 AM – 6:00 PM ADT

Lactation Room

Location: MR505

7:30 AM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:30 AM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

8:30 AM – 12:30 PM ADT

Adherence to Medication

Location: MR202

Lead Speaker: – University of Curacao and VU University Medical Center Amsterdam

Speaker: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

Speaker: – University of Pennsylvania

8:30 AM – 12:30 PM ADT

Advanced Drug Utilization Research: The Conduct of Real-World Drug Utilization Studies: Development And Evaluation of Interventions to Improve the Quality of Medication Use

Location: MR106/107

Lead Speaker: – University Medical Center Groningen

Speaker: – University of Groningen

Speaker: – University of Toronto

Speaker: – Syddansk Universitet

8:30 AM – 12:30 PM ADT

Advanced Methods I: Evidence Synthesis Methods, Living Methods, and Applied Examples in Healthcare Research

Location: Argyle 1

Lead Speaker: – Cerner Enviza an Oracle company

Moderator: – PEPI Consultancy Limited

Speaker: – Institute of Pharmacovigilance Sciences, Drug Safety Research Unit

Speaker: – BeiGene USA, Inc.

8:30 AM – 12:30 PM ADT

Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies

Location: Argyle 2

Lead Speaker: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

Speaker: – Aetion

Speaker: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

Speaker: – Aetion, Inc.

8:30 AM – 12:30 PM ADT

Foundations in Causal Inference

Location: MR201

Lead Speaker: – Harvard School of Public Health

Speaker: – Johnson & Johnson

8:30 AM – 12:30 PM ADT

Introduction to Machine Learning for Pharmacoepidemiologists

Location: Argyle 3

Lead Speaker: – Gilead

Lead Speaker: – Takeda

Speaker: – Boehringer Ingelheim Pharma GmbH & Co. KG

Speaker: – Novartis

Speaker: – IQVIA

8:30 AM – 12:30 PM ADT

Medical Device Epidemiology

Location: MR605

Lead Speaker: – Food and Drug Administration

Speaker: – IQVIA

Speaker: – Biomedical Statistical Consulting

Speaker: – Office of the Chief Medical Officer, Johnson & Johnson

8:30 AM – 12:30 PM ADT

New Frontiers for Pharmacoepidemiology: Using New and Mixed Methods for Data Collection

Location: MR501/502

Lead Speaker: – Dreyer Strategies LLC

Speaker: – IQVIA

Speaker: – The University of Manchester

Speaker: – UNC Injury Prevention Research Center, University of North Carolina, Chapel Hill, NC, USA

12:30 PM – 2:00 PM ADT

Lunch on Your Own

12:45 PM – 2:00 PM ADT

New Member & Early-Stage Investigator Lunch

Location: Ballroom Salon

2:00 PM – 6:00 PM ADT

Advanced Methods II: How to Make Sure Immortal Time Never Happens

Location: Argyle 1

Lead Speaker: – CAUSALab, Harvard T.H. Chan School of Public Health

Moderator: – PEPI Consultancy Limited

Speaker: – RTI Health Solutions

2:00 PM – 6:00 PM ADT

How to Design a Real-World Study of Biologics Including Biosimilars

Location: MR106/107

Lead Speaker: – IQVIA

Speaker: – Amgen, Inc.

Speaker: – Department of Diagnostics and Public Health, University of Verona, Verona

Speaker: – US Food and Drug Administration

2:00 PM – 6:00 PM ADT

Intermediate /Advanced Topics in Vaccine Safety and Effectiveness

Location: MR202

Lead Speaker: – GlaxoSmithKline

Speaker: – Infectious Disease Epidemiology, Moderna Therapeutics Inc.

Speaker: – Merck & Co., Inc.

Speaker: – Office of Vaccines Research and Review, CBER/FDA

Speaker: – Brighton Collaboration

Speaker: – Pfizer Inc

Speaker: – Moderna, Inc

Speaker: – University of Ottawa

Speaker: – University of San Francisco, San Francisco CA, USA

Speaker: – Pfizer

Speaker: – Pfizer, Inc

2:00 PM – 6:00 PM ADT

Modern Pregnancy Pharmacoepidemiology: Non-Live Birth Outcomes

Location: Argyle 2

Lead Speaker: – RTI Health Solutions

Speaker: – Department of Anesthesiology, Perioperative and Pain Medicine, Department of Epidemiology and Population Health, Stanford University School of Medicine

Speaker: – Harvard University

Speaker: – Brigham and Women's Hospital, Harvard Medical School

2:00 PM – 6:00 PM ADT

Pharmacoepidemiologic Approaches to Studying Drug-Drug Interactions

Location: MR201

Lead Speaker: – Brigham and Women's Hospital and Harvard Medical School

Speaker: – Perelman School of Medicine at the University of Pennsylvania

Speaker: – Institute of Clinical Pharmacology and Toxicology, Charité

2:00 PM – 6:00 PM ADT

Pharmacovigilance and Signal Detection

Location: MR605

Lead Speaker: – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School

Lead Speaker: – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration

Speaker: – Uppsala Monitoring Centre

Speaker: – GlaxoSmithKline

2:00 PM – 6:00 PM ADT

Risk Minimization and Communication: Science-Based Approaches and Case Studies for Designing and Evaluating Effective Interventions for the Safe Use of Medicinal Products

Location: Argyle 3

Lead Speaker: – European Medicines Agency

Lead Speaker: – Evidera, Inc

Speaker: – Dutch Medicines Evaluation Board

Speaker: – Loyola University Chicago

Speaker: – Janssen Research & Development, Johnson & Johnson

Speaker: – Health Canada

Speaker: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

6:00 PM – 7:30 PM ADT

Welcome Reception & Academic Showcase

Location: Ballroom Prefunction 5th Floor

7:00 AM – 8:00 AM ADT

Coffee with Exhibitors

Location: Convention Hall

7:00 AM – 8:00 AM ADT

Poster Session A Set-Up

Location: Convention Hall

7:00 AM – 6:00 PM ADT

Lactation Room

Location: MR505

7:00 AM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:00 AM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

8:00 AM – 8:15 AM ADT

Welcome to ICPE 2023

Location: Ballroom

Keynote Speaker: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Keynote Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

8:15 AM – 10:00 AM ADT

Town Hall: Global Regulatory Forum on Real-World Evidence; Sponsored by ISPE's RWE Collaborative SIG

Location: Ballroom

Moderator: – Rutgers, The State University of New Jersey

Keynote Speaker: – U.S. Food and Drug Administration

Keynote Speaker: – Health Canada

Panelist: – Oncology Center of Excellence, US Food and Drug Administration

Panelist: – Health Canada

Panelist: – Pharmaceuticals and Medical Devices Agency

Panelist: – Israel Ministry of Health

Panelist: – European Medicines Agency

Panelist: – Medicines and Healthcare products Regulatory Agency

8:00 AM – 6:00 PM ADT

Exhibits/Poster Session A

Location: Convention Hall

10:00 AM – 10:30 AM ADT

Break/Exhibits/Posters

Location: Convention Hall

10:30 AM – 12:00 PM ADT

Curriculum in Pharmacoepidemiology Training and Alignment with Updated Core Competencies: State of the Field and Educational Needs Assessment

Location: Argyle 1

Lead Speaker: – University of Florida

Speaker: – GW Pharmaceuticals, part of Jazz Pharmaceuticals

Speaker: – PEPI Consultancy Limited

Speaker: – Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky, USA

Speaker: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: – European Medicines Agency

Speaker: – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

Speaker: – U.S. Food and Drug Administration

Speaker: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Speaker: – AbbVie

Speaker: – Optum Epidemiology

Speaker: – National Taiwan University

Speaker: – Pfizer, Inc.

Speaker: – UMKC

Speaker: – UNC Gillings School of Global Public Health

10:30 AM – 12:00 PM ADT

Data to Action: Leveraging Drug Utilization Research to Shift Clinical Practice and Health Policy

Location: Argyle 2

Lead Speaker: – University of Toronto

Speaker: – Syddansk Universitet

Speaker: – University of North Carolina at Chapel Hill

Speaker: – Registry of Senior Australians, South Australian Health and Medical Research Institute

10:30 AM – 12:00 PM ADT

Developing Code Lists for Pharmacoepidemiology: The How and Why?

Location: Argyle 3

Lead Speaker: – Genesis Research

Speaker: – Perelman School of Medicine at the University of Pennsylvania

Speaker: – BeiGene USA, Inc.

Speaker: – Odysseus Data Services Inc.

Speaker: – PPD, a part of Thermo Fisher Scientific

10:30 AM – 12:00 PM ADT

Privacy-Preserving Solutions for Real-World Data (RWD) Access and Collaboration: Challenges & Opportunities

Location: MR201

Lead Speaker: – Merck & Co. Inc.

Speaker: – Merck & Co., Inc., Rahway, NJ, United States

Speaker: – Aetion

Speaker: – Washington University School of Medicine

Speaker: – Replica Analytics

Speaker: – European Medicines Agency

Speaker: – Replica Analytics

10:30 AM – 12:00 PM ADT

Ready or Not, Here Come Estimands! The Emerging Attention to Causal Estimands in Real-World Evidence Studies

Location: MR202

Lead Speaker: – RTI Health Solutions

Speaker: – RTI Health Solutions

Speaker: – CAUSALab, Harvard T.H. Chan School of Public Health

Speaker: – European Medicines Agency

Speaker: – Rutgers University School of Public Health

Speaker: – US Food and Drug Administration

12:00 PM – 1:30 PM ADT

Committee Meetings

12:00 PM – 1:30 PM ADT

Exhibits/Posters

Location: Convention Hall

12:00 PM – 1:30 PM ADT

Lunch

Location: Ballroom

12:15 PM – 1:15 PM ADT

Spotlight Poster Session A

Location: Convention Hall

1:30 PM – 3:00 PM ADT

Applied Methods for Evaluating Effectiveness

Location: Argyle 1

Co-Moderator: – Pfizer

Co-Moderator: – UCL School of Pharmacy, University College London, London, United Kingdom

1:30 PM – 1:45 PM ADT

The Augmentation Therapy and Suicide Risk in Patients with Treatment-Resistant Depression Using Target Trial Emulation Framework

Location: Argyle 1

Presenting Author: – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1:45 PM – 2:00 PM ADT

Long-term effects of intra-articular corticosteroid injections among knee osteoarthritis patients: an instrumental variable and propensity score analysis

Location: Argyle 1

Presenting Author: – University of Bristol

2:00 PM – 2:15 PM ADT

Combining randomized trials and observational studies data for comparison of treatment effects: an application to disease modifying therapies for multiple sclerosis

Location: Argyle 1

Presenting Author: – F. Hoffmann-La Roche Ltd

2:15 PM – 2:30 PM ADT

Comparative effectiveness of generic versus brand-name fluticasone-salmeterol dry powder inhalers to treat COPD

Location: Argyle 1

Presenting Author: – Brigham and Women's Hospital

2:30 PM – 2:45 PM ADT

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

Location: Argyle 1

Presenting Author: – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

2:45 PM – 3:00 PM ADT

Assessing comparability of osteoporosis treatment groups using real world healthcare data from the UK and Denmark: evaluating propensity score and negative control outcome methods to address confounding by indication

Location: Argyle 1

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

1:30 PM – 3:00 PM ADT

Due Before, During, and After Pregnancy

Location: Argyle 2

Co-Moderator: – Department of Epidemiology, Lazio Regional Health Service, Rome

Co-Moderator: – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France

1:30 PM – 1:45 PM ADT

Drug utilisation of valproate-containing medicinal products in women of childbearing potential in 5 European countries: a population-based network cohort study part of DARWIN EU®

Location: Argyle 2

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

1:45 PM – 2:00 PM ADT

Determinants of non-compliance with the pregnancy prevention program in women initiating oral isotretinoin therapy: a cohort study from the French nationwide claims database

Location: Argyle 2

Presenting Author: – Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France

2:00 PM – 2:15 PM ADT

Use of Oral Preventive and Emergency Hormonal Contraceptives: Recent Trends and Response to the U.S. Supreme Court's Dobbs Decision

Location: Argyle 2

Presenting Author: – University of Southern California

2:15 PM – 2:30 PM ADT

New Long-Acting Reversible Contraceptive Insertions More Than Doubled Among a Commercially Insured, U.S.-Based Outpatient Population from 2010 to 2020

Location: Argyle 2

Presenting Author: – UNC Gillings School of Global Public Health

2:30 PM – 2:45 PM ADT

Antithyroid Drug Use Before and During Pregnancy: Assessment of Switching Patterns and Changes Over Time

Location: Argyle 2

Presenting Author: – Leibniz Institute for Prevention Research and Epidemiology - BIPS

2:45 PM – 3:00 PM ADT

Lithium in Pregnancy: A Utilization Study in the Five Nordic Countries

Location: Argyle 2

Presenting Author: – Centre for Pharmacoepidemiology, Karolinska Institutet

1:30 PM – 3:00 PM ADT

Effectiveness of Anticoagulant Therapy

Location: Argyle 3

Co-Moderator: – Harvard Medical School

Co-Moderator: – Georgia State University

1:30 PM – 1:45 PM ADT

Comparative Effectiveness and Safety of Clopidogrel versus Aspirin in Patients With Acute Ischemic Stroke: A Nationwide Population-Based Study

Location: Argyle 3

Presenting Author: – School of Pharmacy, National Taiwan University, Taipei, Taiwan

1:45 PM – 2:00 PM ADT

Effectiveness and Safety of Apixaban, Rivaroxaban and Warfarin in Patients with Advanced Kidney Disease and Atrial Fibrillation: a Nationwide US Cohort Study

Location: Argyle 3

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

2:00 PM – 2:15 PM ADT

Emulating Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Venous Thromboembolism

Location: Argyle 3

Presenting Author: – School of Pharmacy, Sungkyunkwan University, South Korea

2:15 PM – 2:30 PM ADT

Framework for Assessing the Reproducibility of Observational Comparative Effectiveness Research: Direct Oral Anticoagulants and Ischemic or Hemorrhagic Events Case Study

Location: Argyle 3

Presenting Author: – Odysseus Data Services Inc.

2:30 PM – 2:45 PM ADT

The Comparative Effectiveness and Safety of Warfarin, Rivaroxaban, and Apixaban in Patients with Venous Thromboembolism: An Analysis of Three Real-World US Healthcare Databases

Location: Argyle 3

Presenting Author: – Harvard School of Public Health

2:45 PM – 3:00 PM ADT

Effectiveness and Safety of Reduced Dose Prasugrel versus Standard Dose Ticagrelor in East Asian Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Location: Argyle 3

Presenting Author: – School of Pharmacy, National Taiwan University, Taipei, Taiwan

1:30 PM – 3:00 PM ADT

Effectiveness of Antidiabetic Treatments

Location: MR109

Co-Moderator: – CERobs Consulting, LLC

Co-Moderator: – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1:30 PM – 1:45 PM ADT

Heterogenous effects of sodium-glucose cotransporter-2 inhibitors on nephrolithiasis in older adults with type 2 diabetes

Location: MR109

Presenting Author: – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy

1:45 PM – 2:00 PM ADT

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population-Based Cohort Study

Location: MR109

Presenting Author: – Harvard Medical School and Brigham and Women's Hospital

2:00 PM – 2:15 PM ADT

Healthcare utilization and cost associated with Empagliflozin in Older Adults with Type 2 Diabetes: Results from the EMPRISE study

Location: MR109

Presenting Author: – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School

2:15 PM – 2:30 PM ADT

SGLT2 Inhibitors Associated with Decreased Risk of Nephrolithiasis Compared to GLP-1 Receptor Agonists: An Active Comparator, New User Cohort Study

Location: MR109

Presenting Author: – Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

2:30 PM – 2:45 PM ADT

Sodium-Glucose Cotransporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists, and the Risk of Macrovascular, and Microvascular Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Location: MR109

Presenting Author: – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

2:45 PM – 3:00 PM ADT

Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

Location: MR109

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

1:30 PM – 3:00 PM ADT

Health Outcomes Research: What's in a Choice?

Location: MR201

Co-Moderator: – FDA/CDRH/ Office of Clinical Evidence and Analysis

Co-Moderator: – Research Triangle Institute

1:30 PM – 1:45 PM ADT

Association between angiotensin receptor blocker drug recalls and adverse clinical outcomes in patients with heart failure

Location: MR201

Presenting Author: – University of Pittsburgh

1:45 PM – 2:00 PM ADT

Regulatory and health technology assessment of cell and gene therapies in Europe: convergence or divergence?

Location: MR201

Presenting Author: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

2:00 PM – 2:15 PM ADT

Using a target trial framework to compare the effect of high/low opioid dosing strategies at post-surgical discharge on newly developed opioid use disorder

Location: MR201

Presenting Author: – Department of Pharmaceutical Care & Heath Systems, College of Pharmacy, University of Minnesota

2:15 PM – 2:30 PM ADT

Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR): a pragmatic adaptive database-randomized trial

Location: MR201

Presenting Author: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

2:30 PM – 2:45 PM ADT

Personalizing communication to improve medication adherence using reinforcement learning: a pragmatic randomized trial

Location: MR201

Presenting Author: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

2:45 PM – 3:00 PM ADT

Treatment Effectiveness of Oral Disease-Modifying Agent in Multiple Sclerosis Adjusting for Adherence Trajectories

Location: MR201

Presenting Author: – University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy

1:30 PM – 3:00 PM ADT

It Starts at The Very Beginning

Location: MR202

Co-Moderator: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

Co-Moderator: – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA

1:30 PM – 1:45 PM ADT

Health Canada advisory impact on the prevalence and trends of oral codeine use in the Pediatric Canadian population: A comparative study across provinces

Location: MR202

Presenting Author: – Research Centre - CHU Sainte-Justine

1:45 PM – 2:00 PM ADT

The use of ADHD medication and the risk of suicide attempt: A multinational population-based self-controlled case series study

Location: MR202

Presenting Author: – Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, ‐Epidemiology and ‐Economics, University of Groningen, Groningen, The Netherlands

2:00 PM – 2:15 PM ADT

Antidepressant Treatment Initiation Among Children with Long COVID

Location: MR202

Presenting Author: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

2:15 PM – 2:30 PM ADT

The Comparative Effectiveness and Safety of Amoxicillin Alone versus Amoxicillin/Clavulanate for the Outpatient Treatment of Acute Sinusitis in Children

Location: MR202

Presenting Author: – Brigham and Women's Hospital / Harvard Medical School

2:30 PM – 2:45 PM ADT

Early-life cancer risk among children conceived by assisted reproductive technology: A comparative nationwide cohort study from the French National Mother-Child Register "EPI-MERES"

Location: MR202

Presenting Author: – EPI-PHARE

2:45 PM – 3:00 PM ADT

Performance of different computable phenotypes for the identification of opioid-exposed infants in the electronic health record

Location: MR202

Presenting Author: – Department of Health Policy, VUMC

3:00 PM – 3:30 PM ADT

Break/Exhibits/Posters

Location: Convention Hall

3:30 PM – 5:00 PM ADT

Evaluating Challenges in Designing External Control Arm (ECA) Studies to Contextualize Effectiveness in Single-Arm Clinical Trials: A Case in Hematologic Malignancies

Location: Argyle 1

Lead Speaker: – Regeneron Pharmaceuticals

Speaker: – Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Speaker: – Janssen Scientific Affairs, LLC

Speaker: – Eversana Life Science Services, LLC

Speaker: – National Taiwan University

Speaker: – Oncology Center of Excellence, US Food and Drug Administration

3:30 PM – 5:00 PM ADT

Integration of Systems Biology and Pharmacoepidemiology for Drug Repurposing Research: Lessons From the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) Study

Location: Argyle 2

Lead Speaker: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Speaker: – Johns Hopkins University School of Medicine

Speaker: – Clinical and Translational Neuroscience Section, National Institute on Aging, National Institutes of Health

3:30 PM – 5:00 PM ADT

Introducing CoLab: The Evolution of US-Canada International Collaboration on Drug Safety and Effectiveness

Location: Argyle 3

Lead Speaker: – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School

Speaker: – Canadian Agency for Drugs and Technologies in Health

Speaker: – Health Canada

Speaker: – U.S. Food and Drug Administration

Speaker: – McGill University

3:30 PM – 5:00 PM ADT

Leveraging Real-World Insights to Inform Long-term Follow-up for Cell and Gene Therapies: Opportunities for Pharmacoepidemiologists

Location: MR201

Lead Speaker: – Novartis

Speaker: – Pfizer, Inc.

Speaker: – IQVIA

Speaker: – Dutch Medicines Evaluation Board

Speaker: – CSL Behring, King of Prussia, PA, USA

Speaker: – ARS Toscana, Florence, Italy

3:30 PM – 5:00 PM ADT

Sustainable Drug Use: Role of Pharmacoepidemiologists and Their Tools Addressing Environmental Impact of Drug Utilization

Location: MR202

Lead Speaker: – Uppsala university

Speaker: – Faculty or Medicine, University of Novi Sad

Speaker: – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Speaker: – Uppsala University

5:15 PM – 6:45 PM ADT

Fear Not - Get The Shot

Location: Argyle 1

Co-Moderator: – PEPI Consultancy Limited

Co-Moderator: – IQVIA

5:15 PM – 5:30 PM ADT

Reporting Adverse Events Following Immunization in Ghana - Health Care Workers Experiences

Location: Argyle 1

Presenting Author: – Navrongo Health Research Centre

5:30 PM – 5:45 PM ADT

Concordance between analyses from the Moderna global safety database (GSD) and a US population-based study for COVID-19 vaccine, mRNA-1273

Location: Argyle 1

Presenting Author: – Moderna, Inc.

5:45 PM – 6:00 PM ADT

Active vaccine safety surveillance utilizing administrative data: evaluating the use of open + closed claims vs. closed claims alone

Location: Argyle 1

Presenting Author: – Aetion, Inc.

6:00 PM – 6:15 PM ADT

Myocarditis risk following immunization with Spikevax primary series and booster doses in a US administrative database

Location: Argyle 1

Presenting Author: – Moderna, Inc.

6:15 PM – 6:30 PM ADT

Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S.

Location: Argyle 1

Presenting Author: – US Food and Drug Administration

6:30 PM – 6:45 PM ADT

Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly

Location: Argyle 1

Presenting Author: – Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Republic of Korea

5:15 PM – 6:45 PM ADT

Finding Balance in The Rising Tides of Drug Safety in Older Adults: A Global Perspective

Location: Argyle 2

Co-Moderator: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Co-Moderator: – Dalhousie University

5:15 PM – 5:30 PM ADT

Use of cholinesterase inhibitors and non-steroidal anti-inflammatory drugs and the risk of peptic ulcers: a population-based self-controlled case series study

Location: Argyle 2

Presenting Author: – Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

5:30 PM – 5:45 PM ADT

Association of Anticholinergic Burden and Risk of Pneumonia in Aged People

Location: Argyle 2

Presenting Author: – School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan

5:45 PM – 6:00 PM ADT

National Surveillance Using a Clinical Quality Indicator for Prolonged Antipsychotic Use Among Older Australians Living With Dementia Who Access Aged Care Services

Location: Argyle 2

Presenting Author: – UniSA Allied Health & Human Performance, University of South Australia

6:00 PM – 6:15 PM ADT

Effect of Non-benzodiazepine Hypnotics on Motor Vehicle Crashes among Older Adults: A Sequential Target Trial Emulation

Location: Argyle 2

Presenting Author: – Brown University School of Public Health

6:15 PM – 6:30 PM ADT

Association between antihypertensive medication initiation and risk of fractures among older adults in VA long-term care facilities

Location: Argyle 2

Presenting Author: – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

6:30 PM – 6:45 PM ADT

Cumulative sodium-glucose cotransporter 2 inhibitor exposure and incident dementia: a population-based cohort analysis

Location: Argyle 2

Presenting Author: – Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

5:15 PM – 6:45 PM ADT

Lightning Session 1

Location: Argyle 3

Co-Moderator: – Radboud university medical center

Co-Moderator: – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Co-Moderator: – OMNY Health

Co-Moderator: – London School of Hygiene & Tropical Medicine

5:15 PM – 5:20 PM ADT

Trends in Psychotropic Polypharmacy Among Medicaid-Enrolled Youths in One US State, 2015-2020

Location: Argyle 3

Presenting Author: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

5:20 PM – 5:25 PM ADT

Contribution of incident potentially inappropriate medications to polypharmacy-associated mortality in individuals 41-64 years of age

Location: Argyle 3

Presenting Author: – Veterans Aging Cohort Study Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, 06516, USA

5:25 PM – 5:30 PM ADT

Ten-year trajectories of multimorbidity and impact on polypharmacy in older people

Location: Argyle 3

Presenting Author: – Laval University

5:30 PM – 5:35 PM ADT

Depressive Symptoms and Polypharmacy Among Adults: A Population-Based Analysis Using National Health and Nutrition Examination Survey (NHANES) Data

Location: Argyle 3

Presenting Author: – UNC Chapel Hill Gillings School of Global Public Health

5:45 PM – 5:50 PM ADT

Characterizing Medication Use Patterns Among Pregnant and non-Pregnant Patients with COVID-19 in the Sentinel System

Location: Argyle 3

Presenting Author: – Harvard Pilgrim HealthCare & Harvard Medical School

5:50 PM – 5:55 PM ADT

Disorders of glycemic control in child following exposure to antibiotics: a nationwide cohort study

Location: Argyle 3

Presenting Author: – School of Pharmacy, Sungkyunkwan University

5:55 PM – 6:00 PM ADT

Differences in Urinary Tract Infection Incidence During Pregnancy by Racial and Ethnic Group in an Integrated Health System in the US, 2010-2022

Location: Argyle 3

Presenting Author: – Kaiser Permanente Washington Health Research Institute

6:00 PM – 6:05 PM ADT

Prescription Medication Use During Pregnancy in the United States from 2011 to 2019

Location: Argyle 3

Presenting Author: – Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

6:15 PM – 6:20 PM ADT

Urinary Escherichia coli antimicrobial-resistance trends and antibiotic use in Australian Residential Aged Care from 2016 – 2018: an ecological study

Location: Argyle 3

Presenting Author: – University of Technology Sydney

6:20 PM – 6:25 PM ADT

Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease

Location: Argyle 3

Presenting Author: – London School of Hygiene and Tropical Medicine

6:25 PM – 6:30 PM ADT

Increase in Mental Health Conditions and Psychotropic Prescribing in Teenage Girls During the COVID-19 Pandemic in the US

Location: Argyle 3

Presenting Author: – Brigham and Women's Hospital/Harvard Medical School

6:30 PM – 6:35 PM ADT

Non-antibiotic prescription drug use among Danish children and adolescents 2005-2021

Location: Argyle 3

Presenting Author: – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark

5:15 PM – 6:45 PM ADT

Vaccine Potpourri

Location: MR109

Co-Moderator: – University of Pennsylvania School of Medicine

Co-Moderator: – Infectious Disease Epidemiology, Moderna Therapeutics Inc.

5:15 PM – 5:30 PM ADT

The Contribution of Immunization Information System Data to Claims-Based Capture of Vaccines Used to Prevent Mpox and Implications for Claims-Based Mpox Surveillance

Location: MR109

Presenting Author: – Optum Epidemiology

5:30 PM – 5:45 PM ADT

High-Dose Influenza Vaccine Receipt: Geographic Variation in Racial Health Disparities

Location: MR109

Presenting Author: – Brown University School of Public Health

5:45 PM – 6:00 PM ADT

Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. The Vaccine Safety Datalink

Location: MR109

Presenting Author: – Kaiser Permanente Northern California, Vaccine Study Center

6:00 PM – 6:15 PM ADT

Comparing Vaccination Timeliness among U.S. Children in the 2019 and 2021 National Immunization Survey-Child

Location: MR109

Presenting Author: – University of Montana Center for Population Health Research

6:15 PM – 6:30 PM ADT

Statins may modulate the effectiveness of the flu vaccine according to the type of respiratory outcome: Results from the Statin Treatment OPtions during vaccination against inFLUenza (STOPFlu) study

Location: MR109

Presenting Author: – University of Exeter

6:30 PM – 6:45 PM ADT

Assessment of Neurological and Immunological Adverse Events Following Childhood Pneumococcal Vaccination: a Population-Based Self-Controlled Risk Interval Analysis

Location: MR109

Presenting Author: – School of Pharmacy, Sungkyunkwan University, South Korea

5:15 PM – 6:45 PM ADT

Mixing Up The Methods in Drug Utilization Research

Location: MR201

Co-Moderator: – Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland

Co-Moderator: – School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

5:15 PM – 5:30 PM ADT

Approach to standardised drug utilisation analyses in DARWIN EU©

Location: MR201

Presenting Author: – University of Oxford

5:30 PM – 5:45 PM ADT

Using Day-Level Registry Data to Assess Heterogeneous and Time-Varying Medication Exposure Patterns in Patients Receiving Long-Term Outpatient Antibiotic Therapy, 2015-2022

Location: MR201

Presenting Author: – University of North Carolina at Chapel Hill

5:45 PM – 6:00 PM ADT

Projected Impact of Weight-Loss Medication Use on Racial-Ethnic Disparities in Adolescent Obesity

Location: MR201

Presenting Author: – University of Pittsburgh School of Medicine

6:00 PM – 6:15 PM ADT

Approaches to the Description of Patterns of Care after Colitis Diagnosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors (ICIs)

Location: MR201

Presenting Author: – Bristol Myers Squibb

6:15 PM – 6:30 PM ADT

Characteristics of US Middle-Aged Adults with Polypharmacy: An Unsupervised Machine Learning Approach

Location: MR201

Presenting Author: – Panalgo

6:30 PM – 6:45 PM ADT

Assessing the performance of group-based trajectory modelling method to discover patterns of medication adherence

Location: MR201

Presenting Author: – Cytel

5:15 PM – 6:45 PM ADT

COVID Consequences

Location: MR202

Co-Moderator: – Harvard TH Chan School of Public Health

Co-Moderator: – Drug Safety Research Unit

5:15 PM – 5:30 PM ADT

Association between COVID-19 vaccination and healthcare contacts for menstrual disturbance and pre- and post-menopausal bleeding – a nationwide cohort study of 3 million Swedish women

Location: MR202

Presenting Author: – School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

5:30 PM – 5:45 PM ADT

Stroke, Myocardial Infarction, and Pulmonary Embolism after COVID-19 mRNA bivalent booster in People Aged 50 Years or Older

Location: MR202

Presenting Author: – EPI-PHARE (ANSM/CNAM)

5:45 PM – 6:00 PM ADT

Myocarditis associated with SARS-CoV-2 vaccines by dose and brand in three European countries using large electronic health care data sources: a self-controlled risk interval study  in the COVID-19 vaccine monitor study

Location: MR202

Presenting Author: – Department of Biostatistics and Research support, Julius Center for Health sciences and Primary care, University Medical Center Utrecht, the Netherlands

6:00 PM – 6:15 PM ADT

Cerebral Venous Sinus Thrombosis Without Thrombocytopenia After ChAdOx1 nCoV-19 Vaccination

Location: MR202

Presenting Author: – Seoul National University Hospital

6:15 PM – 6:30 PM ADT

Effect of COVID-19 vaccination on thromboembolic and cardiovascular complications following SARS-CoV-2 infection

Location: MR202

Presenting Author: – IDIAP Jordi Gol

6:30 PM – 6:45 PM ADT

Risk of Guillain-Barré syndrome following COVID-19 vaccines: a nationwide self-controlled case series study

Location: MR202

Presenting Author: – EPI-PHARE

7:00 PM – 8:00 PM ADT

SIG Meetings

8:00 PM – 10:00 PM ADT

PDS Editorial Board

Location: MR605

8:30 PM – 11:00 PM ADT

Students/Early Career Professionals Meet & Greet

Location: The Roxbury Urban Dive Bar

7:00 AM – 8:00 AM ADT

RIG Meetings

7:00 AM – 8:00 AM ADT

Coffee with Exhibitors

Location: Convention Hall

7:00 AM – 8:00 AM ADT

Poster Session B Set-Up

Location: Convention Hall

7:00 AM – 6:00 PM ADT

Lactation Room

Location: MR505

7:00 AM – 6:00 PM ADT

Registration

Location: Convention Hall Pre-Function

7:00 AM – 6:00 PM ADT

Speaker Ready Room

Location: MR102

8:00 AM – 9:30 AM ADT

A Tour of Informatics: From Prediction to Prevalence

Location: Argyle 1

Co-Moderator: – ARS Toscana, Florence, Italy

Co-Moderator: – BWH Div of Pharmacoepidemiology and Pharmacoeconomics

8:00 AM – 8:15 AM ADT

Breast Cancer Cohort Comparison among four real-world databases

Location: Argyle 1

Presenting Author: – Merck & Co. Inc.

8:15 AM – 8:30 AM ADT

Comparison of EHR data-completeness in patients with different types of medical insurance coverage in the United States

Location: Argyle 1

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital

8:30 AM – 8:45 AM ADT

Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data

Location: Argyle 1

Presenting Author: – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC

8:45 AM – 9:00 AM ADT

Developing Clinically Interpretable Machine Learning Algorithms for Pressure Injury Safety Surveillance with Explainable AI

Location: Argyle 1

Presenting Author: – Parexel

9:00 AM – 9:15 AM ADT

Brain Metastasis Prediction in Patients with Metastatic Breast Cancer using a U.S. Nationwide Clinico-genomic Database

Location: Argyle 1

Presenting Author: – Genentech, Inc.

9:15 AM – 9:30 AM ADT

Prevalence of probable Alzheimer’s disease in Veteran patients based on clinical notes from electronic health records

Location: Argyle 1

Presenting Author: – EOS

8:00 AM – 9:30 AM ADT

Brainstorm NS Treatments/Exposure

Location: Argyle 2

Co-Moderator: – London School of Hygiene & Tropical Medicine, London

Co-Moderator: – McGill University

8:00 AM – 8:15 AM ADT

Methotrexate and the Risk of Alzheimer’s Disease among U.S. Patients with Rheumatoid Arthritis

Location: Argyle 2

Presenting Author: – Panalgo

8:15 AM – 8:30 AM ADT

Association between gabapentinoids and the risk of severe exacerbations in patients with chronic obstructive pulmonary disease

Location: Argyle 2

Presenting Author: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

8:30 AM – 8:45 AM ADT

Comparative Safety of Alprazolam versus Other Benzodiazepines and Buspirone and Risk of Suicidal Behavior

Location: Argyle 2

Presenting Author: – St John Fisher University/Department of Veteran Affairs

8:45 AM – 9:00 AM ADT

Use of hypnotic-sedative medication and risk of falls and fractures in Danish adults: a self-controlled time-series study

Location: Argyle 2

Presenting Author: – Center for Clincial Research and Prevention, Frederiksberg & Bispebjerg Hospitals

9:00 AM – 9:15 AM ADT

Risk of Osteoporotic Fractures in Menopausal Women with Common Mental Health Problems Using SSRI/SNRI antidepressants: Cohort Study

Location: Argyle 2

Presenting Author: – University college london

9:15 AM – 9:30 AM ADT

Risk of Opioid Overdose with Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors

Location: Argyle 2

Presenting Author: – Brigham and Women's Hospital and Harvard Medical School

8:00 AM – 9:30 AM ADT

Don't Lose Heart

Location: Argyle 3

Co-Moderator: – RTI Health Solutions

Co-Moderator: – Optum Epidemiology

8:00 AM – 8:15 AM ADT

Signal Evaluation Using Observational Databases to Examine Methylphenidate Use and the Risk of Epistaxis

Location: Argyle 3

Presenting Author: – Janssen Research & Development

8:15 AM – 8:30 AM ADT

Statin use and the risk of cancer in patients with heart failure: a target trial emulation

Location: Argyle 3

Presenting Author: – Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom

8:30 AM – 8:45 AM ADT

Sequential Safety Monitoring of Rofecoxib for Cardiovascular Adverse Effects

Location: Argyle 3

Presenting Author: – Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark

8:45 AM – 9:00 AM ADT

Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a target trial emulation study

Location: Argyle 3

Presenting Author: – University of Nottingham

9:00 AM – 9:15 AM ADT

Cardiovascular safety of ibuprofen use for acute pericarditis: A Danish population-based cohort study

Location: Argyle 3

Presenting Author: – Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University

9:15 AM – 9:30 AM ADT

Sclerostin inhibition, cardiovascular biomarkers, risk factors, and clinical outcomes: a Mendelian randomisation analysis using UK Biobank data

Location: Argyle 3

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

8:00 AM – 9:30 AM ADT

Let Us Give it a Trial: Methods in PE

Location: MR109

Co-Moderator: – Optum Epidemiology

Co-Moderator: – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

8:00 AM – 8:15 AM ADT

Conditions for Unbiased Complete Case Analysis in External Control Arms: A Simulation Study

Location: MR109

Presenting Author: – McGill University, Department of Epidemiology, Biostatistics, and Occupational Health

8:15 AM – 8:30 AM ADT

Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies

Location: MR109

Presenting Author: – Johnson & Johnson

8:30 AM – 8:45 AM ADT

A Meta-analysis of bias in Non-Small Cell Lung Cancer external control validation studies using PFS and real-world PFS endpoints

Location: MR109

Presenting Author: – F. Hoffmann-LaRoche Ltd

8:45 AM – 9:00 AM ADT

Evaluation of methods for building a hybrid real-world (RW) control arm for baricitinib Phase IIB randomized controlled trial (RCT) in patients with rheumatoid arthritis (RA)

Location: MR109

Presenting Author: – CorEvitas, LLC

9:00 AM – 9:15 AM ADT

A Bayesian Framework to Summarize Negative Control Outcome Models Assessing the Comparability of Patients Initiating Migraine Preventive Medications

Location: MR109

Presenting Author: – Amgen

9:15 AM – 9:30 AM ADT

Using Negative Control Outcomes to Identify Unmeasured Confounding in a Self-Controlled Risk Interval Study Evaluating the COVID-19 Vaccine Myocarditis Safety Signal

Location: MR109

Presenting Author: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands

8:00 AM – 9:30 AM ADT

Liver and Pregnancy Research Gone Viral

Location: MR201

Co-Moderator: – University of Kentucky College of Pharmacy

Co-Moderator: – University of Montreal

8:00 AM – 8:15 AM ADT

Comparative effectiveness and safety of apixaban and rivaroxaban in cirrhosis and atrial fibrillation

Location: MR201

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital

8:15 AM – 8:30 AM ADT

Comparative effectiveness of non-selective beta blockers in cirrhosis

Location: MR201

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital

8:30 AM – 8:45 AM ADT

Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients with Type 2 Diabetes: A Population-Based Cohort Study

Location: MR201

Presenting Author: – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

8:45 AM – 9:00 AM ADT

Association of Oral Direct-Acting Antiviral Therapy with Development of Parkinson's Disease in Patients with Chronic Hepatitis Virus

Location: MR201

Presenting Author: – Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida

9:00 AM – 9:15 AM ADT

Comparative Effectiveness of the Levonorgestrel (LNG) Implant and Depot Medroxyprogesterone Acetate (DMPA) Injectable for Prevention of Pregnancy among Women Living with HIV on Efavirenz

Location: MR201

Presenting Author: – Gillings School of Global Public Health, University of North Carolina at Chapel Hill

9:15 AM – 9:30 AM ADT

Treating Genital Herpes Infection During Pregnancy to Reduce the Risk of Preeclampsia: A Prospective Cohort Study of more than 89,000 Pregnant Women

Location: MR201

Presenting Author: – Division of Research, Kaiser Foundation Research Institute

8:00 AM – 9:30 AM ADT

With Whom Do We Compare?

Location: MR202

Co-Moderator: – UMKC

Co-Moderator: – Universite Laval

8:00 AM – 8:15 AM ADT

Case Validation in Electronic Health Records linked with a Disease-Specific Clinical Database: Use Case in Pulmonary Arterial Hypertension

Location: MR202

Presenting Author: – Janssen

8:15 AM – 8:30 AM ADT

Does Misclassification due to Electronic Health Record Discontinuity Cause Biased Effect Estimates in Comparative Effectiveness Research?

Location: MR202

Presenting Author: – Brigham and Women's Hospital

8:30 AM – 8:45 AM ADT

International Classification of Diseases (ICD-10) Code Identification of Lab-Confirmed SARS-CoV-2 Within Electronic Health Data

Location: MR202

Presenting Author: – McGill University, Dept. of Medicine and CORE

8:45 AM – 9:00 AM ADT

Using Tree-Based Scan Statistics for Signal Identification: Screening for Elevated Congenital Malformation Risk Following Prenatal Antipsychotic Exposure

Location: MR202

Presenting Author: – Brigham and Women's Hospital/Harvard Medical School

9:00 AM – 9:15 AM ADT

How to underpower your real-world data study: examples and ways to avoid them using quantitative bias analysis

Location: MR202

Presenting Author: – Medical & Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; Department of Medical Statistics

9:15 AM – 9:30 AM ADT

A methodology study to evaluate external comparator arm study results versus randomised controlled trial results: metastatic Hormone-Sensitive Prostate Cancer case study

Location: MR202

Presenting Author: – IQVIA

8:00 AM – 6:00 PM ADT

Exhibits/Poster Session B

Location: Convention Hall

9:30 AM – 10:00 AM ADT

Break/Exhibits/Posters

Location: Convention Hall

10:00 AM – 11:30 AM ADT

Patient Involvement in the Development and Safe Use of Medicines

Location: Ballroom

Moderator: – Loyola University Chicago

Speaker: – European Medicines Agency

Speaker: – N/A

Speaker: – Institute for Public Health and Medicine

Speaker: – Evidera, Inc

Panelist:

11:30 AM – 1:00 PM ADT

Committee Meetings

11:30 AM – 1:00 PM ADT

Exhibits/Posters

Location: Convention Hall

11:30 AM – 1:00 PM ADT

Lunch

Location: Ballroom

11:45 AM – 12:45 PM ADT

Spotlight Poster Session B

Location: Convention Hall

1:00 PM – 2:30 PM ADT

Lightning Session 2

Location: Argyle 1

Co-Moderator: – Regeneron

Co-Moderator: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Co-Moderator: – Food and Drug Administration

Co-Moderator: – Pfizer

1:00 PM – 1:05 PM ADT

Genetic variants and social benefit use in premenopausal breast cancer patients treated with docetaxel: a Danish population-based cohort study

Location: Argyle 1

Presenting Author: – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

1:05 PM – 1:10 PM ADT

Structural Racism and Inequities in Real-World Treatment and Survival Among Patients with Four Solid-Tumor Cancers

Location: Argyle 1

Presenting Author: – Flatiron Health

1:10 PM – 1:15 PM ADT

Patient Diversity and Personalized Treatment of Non-Small Cell Lung Cancer

Location: Argyle 1

Presenting Author: – Syneos Health

1:15 PM – 1:20 PM ADT

Pharmacist Prescribing in Nova Scotia: Uptake and Adaptation to Policy-Related Changes

Location: Argyle 1

Presenting Author: – College of Pharmacy, Dalhousie University

1:30 PM – 1:35 PM ADT

Emulated Target Trial Assessing The Effect Of Empiric Potassium Supplementation On All-Cause Mortality Among Furosemide Initiators

Location: Argyle 1

Presenting Author: – Perelman School of Medicine at the University of Pennsylvania

1:35 PM – 1:40 PM ADT

Effects of SGLT2 inhibitors on anemia in patients with diabetes and chronic kidney disease: A population-based cohort study using target trial emulation framework

Location: Argyle 1

Presenting Author: – Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1:40 PM – 1:45 PM ADT

Risk of stroke with various types of menopausal hormone therapy: A Swedish nationwide Register-based Emulated Target trial

Location: Argyle 1

Presenting Author: – Department of Immunology, Genetics and Pathology, Uppsala University

1:45 PM – 1:50 PM ADT

A causal inference approach to evaluate the effect of Comprehensive Medication Reviews on all-cause mortality among Medicare beneficiaries

Location: Argyle 1

Presenting Author: – Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky, USA

2:00 PM – 2:05 PM ADT

The EU Vaccine Monitoring Platform: a New Framework Leveraging European Union Pharmacoepidemiological Expertise and Data Sources to Monitor the Effectiveness and Safety of Vaccines

Location: Argyle 1

Presenting Author: – European Medicines Agency

2:05 PM – 2:10 PM ADT

VAC4EU Study Tracking Post-Authorization Safety of mRNA-1273 in Five European Countries: How to Overcome the Methodological Challenges

Location: Argyle 1

Presenting Author: – Julius Clinical Research

2:10 PM – 2:15 PM ADT

The Contribution of Immunization Information System Data to Claims-Based Vaccine Administration Capture Over Time and Implications for Claims-Based COVID-19 Vaccine Studies

Location: Argyle 1

Presenting Author: – Optum Epidemiology

2:15 PM – 2:20 PM ADT

Interpretating Relative Vaccine Effectiveness: Challenges and Real Examples from the REFORCO-Brazil Study on COVID-19 Vaccines

Location: Argyle 1

Presenting Author: – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK

1:00 PM – 2:30 PM ADT

Risky Business...

Location: Argyle 2

Co-Moderator: – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

Co-Moderator: – US Food and Drug Administration

1:00 PM – 1:15 PM ADT

Benzodiazepine use early in pregnancy and risk of congenital malformations

Location: Argyle 2

Presenting Author: – Stanford University

1:15 PM – 1:30 PM ADT

Risk of preterm birth associated with ADHD medication use in pregnancy

Location: Argyle 2

Presenting Author: – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health

1:30 PM – 1:45 PM ADT

Prenatal exposure to selective serotonin reuptake inhibitors and risk of Disorders of Gut-Brain Interaction in the offspring

Location: Argyle 2

Presenting Author: – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark

1:45 PM – 2:00 PM ADT

Antiseizure Medication During Pregnancy and Offspring Neurodevelopmental Outcomes: A Study of Two Cohorts from the UK and Sweden

Location: Argyle 2

Presenting Author: – Karolinska Institutet

2:00 PM – 2:15 PM ADT

Comparing Long-term Neurodevelopmental Outcomes in Children with Prenatal Exposure to Buprenorphine and Methadone: A Population-based Study

Location: Argyle 2

Presenting Author: – University of Rhode Island

2:15 PM – 2:30 PM ADT

Fetal and Early Life Exposure to Antibiotics and the Risk of Neurodevelopmental Disorders: A Nationwide Population-Based Cohort Study with Sibling Analysis

Location: Argyle 2

Presenting Author: – School of Pharmacy, Sungkyunkwan University

1:00 PM – 2:30 PM ADT

Safety in Numbers: A Potpourri

Location: Argyle 3

Co-Moderator: – Institute of Clinical Pharmacology and Toxicology, Charité

Co-Moderator: – Leibniz Institute for Prevention Research and Epidemiology - BIPS

1:00 PM – 1:15 PM ADT

Use of Proton Pump Inhibitors and Risk of Severe COVID-19: A Case-Control Study in U.S. Medicare Beneficiaries

Location: Argyle 3

Presenting Author: – Acumen, LLC

1:15 PM – 1:30 PM ADT

The Risk of Acute Transverse Myelitis after COVID-19 Vaccination: Self-Controlled Case Series Study

Location: Argyle 3

Presenting Author: – Department of Health Convergence, Ewha Womans University

1:30 PM – 1:45 PM ADT

Comparative Safety of Antibiotics for the Treatment of Outpatient Community-Acquired Pneumonia

Location: Argyle 3

Presenting Author: – Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine

1:45 PM – 2:00 PM ADT

Comparative risk of hepatitis C virus infection in patients with rheumatoid arthritis receiving target-synthetic disease-modified anti-rheumatic drugs (tsDMARDs) vs. biological DMARDs (bDMARDs): a population-based study

Location: Argyle 3

Presenting Author: – Institute of Clinical Pharmacy and Pharmaceutical Sciences (CPPS), College of Medicine, National Cheng Kung University, Tainan, Taiwan.

2:00 PM – 2:15 PM ADT

Potential Drug-Drug Interactions Among U.S. Adults Treated With Nirmatrelvir/Ritonavir (Paxlovid): A Cross-sectional Study Of The National COVID Cohort Collaborative (N3C)

Location: Argyle 3

Presenting Author: – Johns Hopkins Bloomberg School of Public Health

2:15 PM – 2:30 PM ADT

Real-World Data to Evaluate Severe Acute Liver Injury After Outpatient Initiation of Potentially Hepatotoxic Medications: A Series of Nationwide Cohort Studies

Location: Argyle 3

Presenting Author: – Perelman School of Medicine at the University of Pennsylvania

1:00 PM – 2:30 PM ADT

The "Sea" of Cancer

Location: MR109

Co-Moderator: – Oncology Center of Excellence, US Food and Drug Administration

Co-Moderator: – BeiGene USA, Inc.

1:00 PM – 1:15 PM ADT

Trajectories of Antidepressant Adherence Before Tamoxifen Initiation Among US Women with Breast Cancer

Location: MR109

Presenting Author: – University of Maryland, Baltimore/Carelon Research

1:15 PM – 1:30 PM ADT

The Association Between Pre-Existing Type 2 Diabetes on Breast Cancer-Related and Overall Mortality Among Women with Breast Cancer

Location: MR109

Presenting Author: – McGill University

1:30 PM – 1:45 PM ADT

Risk of Childhood Leukemia and Lymphoma after In-utero Exposure to Maternal Diabetes and Antidiabetics – a Nordic Population-based Study

Location: MR109

Presenting Author: – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

1:45 PM – 2:00 PM ADT

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Location: MR109

Presenting Author: – Regeneron Pharmaceuticals

2:00 PM – 2:15 PM ADT

Maintenance proton pump inhibitor usage and risk of colorectal cancer: A population-based Swedish cohort study

Location: MR109

Presenting Author: – Karolinska Institutet

2:15 PM – 2:30 PM ADT

Multiple models to evaluate the prognostic factors of disease progression after R0 esophagectomy for Chinese patients with squamous cell carcinoma

Location: MR109

Presenting Author: – Global Epidemiology, Office of Chief Medical Officer, Johnson & Johnson, China

1:00 PM – 2:30 PM ADT

Vaccines: Boosting Confidence

Location: MR201

Co-Moderator: – Merck

Co-Moderator: – Pfizer

1:00 PM – 1:15 PM ADT

Effectiveness of BNT162b2 COVID-19 Vaccine in US Children Aged 5-17 Years

Location: MR201

Presenting Author: – Optum Epidemiology

1:15 PM – 1:30 PM ADT

Short-Term Effectiveness of Bivalent COVID-19 mRNA Booster Vaccinations in the Veterans Health Administration Using Self-Controlled Risk Interval and Test-Negative Case-Control Designs

Location: MR201

Presenting Author: – White River Junction Veterans Affairs Medical Center, White River Junction, VT

1:30 PM – 1:45 PM ADT

COVID-19 vaccine effectiveness against Post COVID-19 condition – A register-based cohort study among 589,722 individuals in Sweden

Location: MR201

Presenting Author: – Department of Microbiology and Immunology, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

1:45 PM – 2:00 PM ADT

Risk of Breakthrough SARS-CoV-2 Infection and Clinical Outcomes Among Patients with Type 2 Diabetes

Location: MR201

Presenting Author: – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

2:00 PM – 2:15 PM ADT

Associations between HLA variations and serological response to COVID-19 vaccination: an analysis of UK Biobank antibody survey data

Location: MR201

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

2:15 PM – 2:30 PM ADT

The impact of HLA-DQB1*06 alleles on COVID-19 vaccine effectiveness: an analysis of SARS-CoV-2 antibodies and breakthrough infections based on UK Biobank

Location: MR201

Presenting Author: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

1:00 PM – 2:30 PM ADT

Drug Safety in Diabetes

Location: MR202

Co-Moderator: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Co-Moderator: – Regeneron Pharmaceuticals, Inc., Tarrytown, NY

1:00 PM – 1:15 PM ADT

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Fractures in Postmenopausal Women with Type 2 Diabetes: A Nationwide Cohort Study

Location: MR202

Presenting Author: – School of Pharmacy, Sungkyunkwan University

1:15 PM – 1:30 PM ADT

Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A Post-Authorization Safety Study

Location: MR202

Presenting Author: – Boehringer Ingelheim International GmbH

1:30 PM – 1:45 PM ADT

Insulin use in type 2 diabetes and the risk of dementia: A comparative population-based cohort study

Location: MR202

Presenting Author: – University of Waterloo

1:45 PM – 2:00 PM ADT

Fluoroquinolones and the risk of severe hypoglycemia among sulfonylurea users

Location: MR202

Presenting Author: – Department of Medicine, McGill University, Montreal, QC, Canada

2:00 PM – 2:15 PM ADT

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Biliary Tract Diseases Among Patients With Type 2 Diabetes

Location: MR202

Presenting Author: – McGill University

2:15 PM – 2:30 PM ADT

Ambient Heat, Exogenous Insulin, and Risk of Hypoglycemia Among Older Medicare Beneficiaries with Diabetes

Location: MR202

Presenting Author: – Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

2:40 PM – 3:50 PM ADT

Annual Meeting of ISPE Members & Awards Ceremony

Location: Ballroom

Keynote Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Keynote Speaker: – Regeneron Pharmaceuticals, Inc.

Keynote Speaker: – International Society for Pharmacoepidemiology

3:50 PM – 4:15 PM ADT

Break/Exhibits/Posters

Location: Convention Hall

4:15 PM – 5:45 PM ADT

Building Consensus on RWE Evaluation: Standardized Tool for Assessing Validity in RWE Studies of Medication Safety and Effectiveness

Location: Argyle 1

Lead Speaker: – Brigham and Women's Hospital and Harvard Medical School

Speaker: – Optum Epidemiology

Speaker: – CERobs Consulting, LLC

Speaker: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Speaker: – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School

4:15 PM – 5:45 PM ADT

From Classic to Cutting Edge: Addressing Data Quality Challenges in Electronic Health Record Data

Location: Argyle 2

Lead Speaker: – UNC Chapel Hill Gillings School of Global Public Health

Speaker: – AstraZeneca

Speaker: – National Cancer Institute (NCI)

Speaker: – Epividian

4:15 PM – 5:45 PM ADT

Person-generated Health Data: Is Pharmacoepidemiology Ready for this New Frontier?

Location: Argyle 3

Lead Speaker: – GSK

Speaker: – Food and Drug Administration

Speaker: – Office of the Chief Medical Officer, Johnson & Johnson

Speaker: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Speaker: – The University of Manchester

4:15 PM – 5:45 PM ADT

Sharing is Caring? A Symposium on Code Sharing in Pharmacoepidemiology

Location: MR201

Lead Speaker: – London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT

Speaker: – London School of Hygiene and Tropical Medicine

Speaker: – Medicines and Healthcare products Regulatory Agency

Speaker: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

Speaker: – ARS Toscana, Florence, Italy

Speaker: – London School of Hygiene & Tropical Medicine, London

Speaker: – University of Oxford, Erasmus MC University

Speaker: – Brigham and Women's Hospital, Harvard Medical School

Speaker: – Queen Mary University of London

Speaker: – GSK

Speaker: – European Medicines Agency

4:15 PM – 5:45 PM ADT

Translating Real-World Evidence and Other Pharmacoepidemiological Research Findings into Policy and Clinical Practice: How Well are We Doing and What are the Opportunities for Improvement?

Location: MR202

Lead Speaker: – Evidera, Inc

Speaker: – Perelman School of Medicine at the University of Pennsylvania

Speaker: – Oncology Center of Excellence, US Food and Drug Administration

Speaker: – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

6:00 PM – 7:00 PM ADT

Council Meetings

7:00 PM – 11:00 PM ADT

Social Evening at the Grafton Connor Downtown Complex

Location: Grafton Connor Downtown Complex

7:00 AM – 8:00 AM ADT

Coffee with Exhibitors

Location: Convention Hall

7:00 AM – 8:00 AM ADT

Poster Session C Set-Up

Location: Convention Hall

7:00 AM – 8:00 AM ADT

SIG Meetings

7:00 AM – 3:30 PM ADT

Speaker Ready Room

Location: MR102

7:00 AM – 4:30 PM ADT

Lactation Room

Location: MR505

7:00 AM – 4:30 PM ADT

Registration

Location: Convention Hall Pre-Function

7:15 AM – 8:15 AM ADT

2024 Scientific Program Committee

Location: MR605

8:00 AM – 1:30 PM ADT

Exhibits

Location: Convention Hall

8:00 AM – 1:30 PM ADT

Poster Session C

Location: Convention Hall

8:30 AM – 10:00 AM ADT

Beyond the Beaver Tail in Clinical Epidemiology

Location: Argyle 1

Co-Moderator: – Perelman School of Medicine at the University of Pennsylvania

Co-Moderator: – European Medicines Agency

8:30 AM – 8:45 AM ADT

Association between Dietary Supplement Use and Mortality among US Adults with Diabetes: a Longitudinal Cohort Study

Location: Argyle 1

Presenting Author: – School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong

8:45 AM – 9:00 AM ADT

Frequency of Vaso-Occlusive Crises Among Patients with Severe Sickle Cell Disease Receiving Standard-of-Care Treatment

Location: Argyle 1

Presenting Author: – Vertex Pharmaceuticals

9:00 AM – 9:15 AM ADT

Sickle Cell Disease Acute Event Frequencies in the United States – A Retrospective Cohort Study Using Optum Electronic Health Records

Location: Argyle 1

Presenting Author: – Pfizer Inc.

9:15 AM – 9:30 AM ADT

Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Comparing Female Patients with Recurrent Versus Non-recurrent Uncomplicated Urinary Tract Infection in the United States

Location: Argyle 1

Presenting Author: – Analysis Group, Inc., Boston, MA, USA

9:30 AM – 9:45 AM ADT

Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: a cohort study using the PHARMO Data Network

Location: Argyle 1

Presenting Author: – PHARMO Institute for Drug Outcomes Research

9:45 AM – 10:00 AM ADT

Trends in prescribing preferences for anticoagulants among non-valvular atrial fibrillation patients in the UK with and without chronic kidney disease, 2010-2020

Location: Argyle 1

Presenting Author: – Rutgers University

8:30 AM – 10:00 AM ADT

Pharmacoepi Toolbox for Confounding Control

Location: Argyle 2

Co-Moderator: – University of Southern Denmark

Co-Moderator: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands

8:30 AM – 8:45 AM ADT

Principled Approaches To Handle Partially Observed Confounder Data From Electronic Health Records: A Plasmode Simulation Study

Location: Argyle 2

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

8:45 AM – 9:00 AM ADT

Accounting for treatment switching by pairwise censoring: Is this needed, sufficient to mitigate attrition bias, or should more advanced methodology be used?

Location: Argyle 2

Presenting Author: – Medical & Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; Department of Medical Statistics

9:00 AM – 9:15 AM ADT

Orthogonalized regression for causal inference: a pharmacoepidemiologist’s dream?

Location: Argyle 2

Presenting Author: – TargetRWE

9:15 AM – 9:30 AM ADT

Use of Standardization to Increase the Precision of Site-Specific Estimates in Multi-Site Studies and Distributed Networks

Location: Argyle 2

Presenting Author: – McGill University, Department of Epidemiology, Biostatistics, and Occupational Health

9:30 AM – 9:45 AM ADT

Nonparametric Assignment of Stratum Membership to Achieve Covariate Balance in Small Cohorts

Location: Argyle 2

Presenting Author: – Harvard TH Chan School of Public Health

9:45 AM – 10:00 AM ADT

Using Inverse Odds Weights to Separate Modification from Better Confounding Control When Restricting on Covariates

Location: Argyle 2

Presenting Author: – McGill University, Department of Epidemiology, Biostatistics, and Occupational Health

8:30 AM – 10:00 AM ADT

Pharmacovigilance: Follow the Evidence

Location: Argyle 3

Co-Moderator: – AbbVie, Inc.

Co-Moderator: – Regeneron Pharmaceuticals, Inc.

8:30 AM – 8:45 AM ADT

On the use of different reference sets in data mining spontaneous reports for pharmacovigilance

Location: Argyle 3

Presenting Author: – School of Epidemiology and Public Health, University of Ottawa

8:45 AM – 9:00 AM ADT

Statistical Outlier Detection to Identify Uncoded High-Dose Case Reports in VigiBase for Medication Error Signals

Location: Argyle 3

Presenting Author: – Uppsala Monitoring Centre

9:00 AM – 9:15 AM ADT

Development and evaluation of phenotype algorithms for the European Medicines Agency designated medical events in a network of real-world data

Location: Argyle 3

Presenting Author: – Janssen Research & Development

9:15 AM – 9:30 AM ADT

Application of new signal detection methods to EUROmediCAT data: Bayesian Confidence Propagation Neural Network-Biclustering (BCPNN-Bic) and BCPNN-Bicluster-Bayesian Hierarchical Modelling (BBBHM)

Location: Argyle 3

Presenting Author: – St George's, University of London

9:30 AM – 9:45 AM ADT

Signal detection using longitudinal healthcare claims data; a pilot study using Lantus as case drug

Location: Argyle 3

Presenting Author: – IQVIA

9:45 AM – 10:00 AM ADT

Investigating Potential Differences in the Safety Profiles of Biosimilars relative to Originator Products using a Tree-Based Scan Statistic

Location: Argyle 3

Presenting Author: – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration

8:30 AM – 10:00 AM ADT

Mapping the Road to Health Equity/Equality

Location: MR109

Co-Moderator: – The Ohio State University

Co-Moderator: – Epi Excellence LLC

8:30 AM – 8:45 AM ADT

Disparities in the Uptake of Newer Second-Line Antidiabetic Therapies among Medicare Beneficiaries

Location: MR109

Presenting Author: – Center for Pharmacoepidemiology and Treatment Sciences, Rutgers University/ Daiichi Sankyo, Inc.

8:30 AM – 10:00 AM ADT

Regional deprivation and stocking of Meningococcal vaccines in the United States: Does location matter?

Location: MR109

Presenting Author: – Pfizer, Inc

8:45 AM – 9:00 AM ADT

Socioeconomic position and adherence to adjuvant endocrine therapy in premenopausal breast cancer patients – a Danish population-based cohort study

Location: MR109

Presenting Author: – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

9:00 AM – 9:15 AM ADT

A Pan-Formulary Analysis of the Association Between Community Pharmacy Dispensations with Local Area-Level Deprivation in England

Location: MR109

Presenting Author: – Health Analytics, Lane Clark & Peacock LLP

9:30 AM – 9:45 AM ADT

Racial Disparities in Paxlovid Use Treating for High Risk COVID-19 Patients – A Large Population Based Study Using US Claim Data

Location: MR109

Presenting Author: – Pfizer Inc

9:45 AM – 10:00 AM ADT

Mediators of Racial/Ethnic Inequities in Clinical Trial Participation among US Patients with Cancer, 2011-2022

Location: MR109

Presenting Author: – University of Southern California

8:30 AM – 10:00 AM ADT

Self-Controlled and Other Methods Stuff

Location: MR201

Co-Moderator: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Co-Moderator: – Graduate School of Medicine, The University of Tokyo

8:30 AM – 8:45 AM ADT

Hypersensitivity of self-controlled designs towards exposure misclassification when there is abundant chronic use - a simulation study

Location: MR201

Presenting Author: – University of Southern Denmark

8:45 AM – 9:00 AM ADT

Real World Evidence BRIDGE (BRing Intelligence about Data to Generation of Evidence): a method to connect protocol with programming practice

Location: MR201

Presenting Author: – UMC Utrecht

9:00 AM – 9:15 AM ADT

Diagnosing informative left truncation due to delayed cohort entry in clinico-genomic real-world data

Location: MR201

Presenting Author: – Bristol Myers Squibb

9:15 AM – 9:30 AM ADT

An analytic method to weight longitudinal treatment patterns for visualization with Sankey diagrams

Location: MR201

Presenting Author: – University of North Carolina at Chapel Hill

9:30 AM – 9:45 AM ADT

Adjusting for unmeasured confounding bias in the Statin Treatment OPtions during vaccination against Flu (STOPFlu) study: an application of the Prior Event Rate Ratio Pairwise method

Location: MR201

Presenting Author: – University of Munster, Germany

9:45 AM – 10:00 AM ADT

Is the sequence ratio an unbiased estimate of the incidence rate ratio? A simulation study

Location: MR201

Presenting Author: – Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark.

8:30 AM – 10:00 AM ADT

Tracking Trends Around The World

Location: MR202

Co-Moderator: – Cytel

Co-Moderator: – FISABIO

8:30 AM – 8:45 AM ADT

Gabapentinoid Consumption In 65 Countries and Regions From 2008 to 2018: A Longitudinal Study

Location: MR202

Presenting Author: – UCL School of Pharmacy

8:45 AM – 9:00 AM ADT

Is zolpidem still the top medication used for insomnia? Trends in dispensing of zolpidem and low-dose trazodone for new and continued use among commercially insured US adults, 2011-2021

Location: MR202

Presenting Author: – Harvard Medical School & Harvard Pilgrim Health Care Institute

9:00 AM – 10:00 AM ADT

National trends in antidepressant utilisation within Australian residential aged care facilities, 2006-2019

Location: MR202

Presenting Author: – UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia

9:15 AM – 9:30 AM ADT

The Risk of Serious Opioid-Related Harms Associated With Discharge Opioid and Non-Opioid Analgesic ‎Regimens Among Patients Hospitalized With Long-Bone Fracture

Location: MR202

Presenting Author: – Department of Health Policy, VUMC

9:30 AM – 9:45 AM ADT

Prescribing of Opioid Analgesics in Germany: Opposite Trends When Different Quantification Measures Are Used

Location: MR202

Presenting Author: – Leibniz Institute for Prevention Research and Epidemiology – BIPS

9:45 AM – 10:00 AM ADT

Tramadol use in the United States, 2004-2021

Location: MR202

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital / Harvard Medical School, Boston MA

10:00 AM – 10:30 AM ADT

Break/Exhibits/Posters

Location: Convention Hall

10:30 AM – 12:00 PM ADT

Bias Introduced by COVID-19 Related Healthcare Disruptions in Safety and Effectiveness Studies: Proposing Methodological Solutions

Location: Argyle 1

Lead Speaker: – GSK

Speaker: – Analysis Group, Inc., Boston, MA, USA

Speaker: – European Medicines Agency

Speaker: – GSK

Speaker: – Analysis Group, Inc

Speaker: – London School of Hygiene & Tropical Medicine, London

10:30 AM – 12:00 PM ADT

Deep Learning for Pharmacoepidemiologists: An Accessible Introduction to Neural Networks

Location: Argyle 2

Lead Speaker: – IQVIA

Speaker: – Gilead

Speaker: – Novartis

Speaker: – Takeda

Speaker: – IQVIA

10:30 AM – 12:00 PM ADT

Emulation of a Target Trial in Pregnancy: Learning from the Chronic Hypertension And Pregnancy (CHAP) Trial

Location: Argyle 3

Lead Speaker: – University of California San Diego

Speaker: – University of California San Diego

Speaker: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Speaker: – Kaiser Permanente Washington Health Research Institute

Speaker: – Department of Obstetrics and Gynecology, Vanderbilt University Medical Center

10:30 AM – 12:00 PM ADT

Optimizing Therapeutic Decision-making for Off-Label Medicines Use: Challenges and Opportunities for Improving Practice and Research in the Age of Real-World Evidence (RWE)

Location: MR201

Lead Speaker: – Faculty of Medicine & Health, University of New South Wales, Sydney, 2052, Australia

Speaker: – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA

Speaker: – University of British Columbia

Speaker: – University of Maryland, Baltimore

Speaker: – GSK

Speaker: – Nationwide Children's Hospital

Speaker: – University of Maryland School of Pharmacy, Baltimore, Maryland, USA

10:30 AM – 12:00 PM ADT

Scaling-up Real-World Evidence Generation for Regulators in Europe: DARWIN EU

Location: MR202

Lead Speaker: – University of Oxford, Erasmus MC University

Speaker: – Department of Medical Informatics, Erasmus MC University

Speaker: – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Speaker: – European Medicines Agency

Speaker: – Johnson & Johnson

Speaker: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Speaker: – Department of Medical Informatics, Erasmus University Medical Center

Speaker: – European Medicines Agency

Speaker: – Bayer AG

12:00 PM – 1:30 PM ADT

Exhibits/Posters

Location: Convention Hall

12:00 PM – 1:30 PM ADT

ISPE Board of Directors' Lunch & Meeting

Location: MR604

12:00 PM – 1:30 PM ADT

Lunch

Location: Ballroom

12:15 PM – 1:15 PM ADT

Spotlight Poster Session C

Location: Convention Hall

1:30 PM – 3:00 PM ADT

Hali-FACTS: Navigating Benefit-Risk Decision-Making with RWE (sponsored by BRACE SIG)

Location: Argyle 1

Co-Moderator: – Eli Lilly and Company

Co-Moderator: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

Co-Moderator: – Copenhagen Centre for Regulatory Science, University of Copenhagen

1:30 PM – 1:45 PM ADT

Benefit-Risk Assessment to Support the FDA’s Decision on Vaccines for SARS-CoV-2

Location: Argyle 1

Presenting Author: – FDA/CBER/OBPV

1:45 PM – 2:00 PM ADT

Rethinking survey samples in patient preference studies: a first-degree relative sample versus a general public proxy sample in rheumatoid arthritis prevention

Location: Argyle 1

Presenting Author: – Janssen Research & Development

2:00 PM – 2:15 PM ADT

Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of valproates

Location: Argyle 1

Presenting Author: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

2:15 PM – 2:30 PM ADT

Prenatal Exposure to Valproic Acid in the United States

Location: Argyle 1

Presenting Author: – Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida

2:30 PM – 2:45 PM ADT

Assessment of the Effectiveness of Risk Evaluation and Mitigation Strategy for the Prevention of Fetal Exposure to Phentermine-Topiramate Using Two Large Nationwide Cohorts

Location: Argyle 1

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

2:45 PM – 3:00 PM ADT

A descriptive observational cohort study to assess effectiveness of risk minimization activities in baricitinib incident users treated for rheumatoid arthritis in Nordic countries

Location: Argyle 1

Presenting Author: – Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg

1:30 PM – 3:00 PM ADT

Lightning Session 3

Location: Argyle 2

Co-Moderator: – RTI Health Solutions

Co-Moderator: – Janssen Research & Development

Co-Moderator: – Regeneron Pharmaceuticals, Inc.

Co-Moderator: – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia

1:30 PM – 1:35 PM ADT

Comparative Cardiovascular Risk Associated with Enzalutamide and Abiraterone Use in Patients with Metastatic Castration-Resistant Prostate Cancer

Location: Argyle 2

Presenting Author: – Institution of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky

1:35 PM – 1:40 PM ADT

Cardiovascular Risks in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy among the Southern Chinese: a Population-based Cohort Study

Location: Argyle 2

Presenting Author: – The University of Hong Kong

1:40 PM – 1:45 PM ADT

Risk of thyroid cancer associated with incretin-based drugs among patients with type 2 diabetes

Location: Argyle 2

Presenting Author: – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

1:45 PM – 1:50 PM ADT

Comparison of Tisagenlecleucel With Historical Treatments For Relapsed or Refractory Diffuse Large B-cell Lymphoma: a Retrospective Study Using External Comparator From the Korean Lymphoma Registry Data

Location: Argyle 2

Presenting Author: – School of Pharmacy, Sungkyunkwan University, South Korea

2:00 PM – 2:05 PM ADT

COVID-19 Vaccination and the Risk of Abnormal Uterine Bleeding: a population-based self-controlled case series study

Location: Argyle 2

Presenting Author: – Department of Health Convergence, Ewha Womans University

2:05 PM – 2:10 PM ADT

Incidence of Diabetes Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study

Location: Argyle 2

Presenting Author: – The University of Hong Kong

2:10 PM – 2:15 PM ADT

Safety Monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 Vaccines in U.S. Children aged 5-17 years

Location: Argyle 2

Presenting Author: – US Food and Drug Administration

2:15 PM – 2:20 PM ADT

Safety of COVID-19 mRNA Vaccination among Young Children in the Vaccine Safety Datalink

Location: Argyle 2

Presenting Author: – Kaiser Permanente Vaccine Study Center - Kaiser Permanente Northern California

2:30 PM – 2:35 PM ADT

Quantifying the Impact of Novel Metastatic Cancer Therapies on Health Disparities in Survival Outcomes Based on Published Aggregate Data

Location: Argyle 2

Presenting Author: – Lumen Value & Access, Healthcare Consultancy Group

2:35 PM – 2:40 PM ADT

Enhancing Clinical Trials By Linking Them to Real-World Data

Location: Argyle 2

Presenting Author: – Medidata AI

2:40 PM – 2:45 PM ADT

Using Real-World Data to Evaluate Trends in Female Elective Contraception Procedures Among Women of Childbearing Age Surrounding Key Legal and Policy Events From 2008 to 2022

Location: Argyle 2

Presenting Author: – CVS Health

2:45 PM – 2:50 PM ADT

Use of Antiepileptic Drugs During Pregnancy in France between 2010 and 2021

Location: Argyle 2

Presenting Author: – EPI-PHARE

1:30 PM – 3:00 PM ADT

The COVID-19 Lobster Trap

Location: Argyle 3

Co-Moderator: – University of Oxford, Erasmus MC University

Co-Moderator: – Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky, USA

1:30 PM – 1:45 PM ADT

Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People With Type 2 Diabetes

Location: Argyle 3

Presenting Author: – PHARMO Institute for Drug Outcomes Research

1:45 PM – 2:00 PM ADT

Impact of COVID-19 Pandemic Restrictions on Diagnosis and Treatment of Hypertension in the United Kingdom

Location: Argyle 3

Presenting Author: – Mcgill University Department of Epidemiology, Biostatistics, and Occupational Health

2:00 PM – 2:15 PM ADT

Impact of the COVID-19 Pandemic on Drug Shortage Incidence in the United States

Location: Argyle 3

Presenting Author: – Department of Medicine, Division of General Internal Medicine, University of Pittsburgh School of MedicineDepartment of Health Policy and Management, University of Pittsburgh School of Public Health

2:15 PM – 2:30 PM ADT

A dynamic prognostic model for identifying vulnerable COVID-19 patients at high risk of rapid deterioration

Location: Argyle 3

Presenting Author: – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital

2:30 PM – 2:45 PM ADT

Hospitalized Arterial and Venous Thrombotic Events in Patients Diagnosed in the Ambulatory Setting with COVID-19 Compared to Influenza

Location: Argyle 3

Presenting Author: – Harvard Pilgrim Health Care Institute

2:45 PM – 3:00 PM ADT

Defining Post-COVID Conditions Using Changes in Symptomatology in Electronic Health Record Data from the United States

Location: Argyle 3

Presenting Author: – Pfizer

1:30 PM – 3:00 PM ADT

Timing is Everything

Location: MR109

Co-Moderator: – RTI Health Solutions

Co-Moderator: – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill

1:30 PM – 1:45 PM ADT

Are Major Congenital Malformations (MCMs) Identifiable Among Claims for Non-Live Births?

Location: MR109

Presenting Author: – Optum Epidemiology

1:45 PM – 2:00 PM ADT

Validity of Algorithms for Congenital Malformations in United States Claims, Registry, and Surveillance Databases: A Systematic Literature Review

Location: MR109

Presenting Author: – IQVIA

2:00 PM – 2:15 PM ADT

Identifying pediatric patients for an external control arm for a set of rare disease trials using multiple administrative healthcare data sources: lessons from the road

Location: MR109

Presenting Author: – Carelon Research

2:15 PM – 2:30 PM ADT

Triple challenges – Small sample sizes in both exposure and control groups when scanning rare maternal outcomes in signal identification: A simulation study

Location: MR109

Presenting Author: – Harvard Pilgrim Health Care Institute/Harvard Medical School

2:30 PM – 2:45 PM ADT

Factors Associated with Abortion of Women with Systemic Lupus Erythematosus (SLE): Using a National Claims Database in Korea

Location: MR109

Presenting Author: – Chung-Ang University

2:45 PM – 3:00 PM ADT

No time to lose – prenatal exposure to teratogenic medications and new abortion laws in the United States

Location: MR109

Presenting Author: – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

1:30 PM – 3:00 PM ADT

Massive Mabs

Location: MR201

Co-Moderator: – University of Toronto

Co-Moderator: – University of Lagos

1:30 PM – 1:45 PM ADT

Longitudinal associations between body mass index and disease activity, and radiographic progression in rheumatoid arthritis patients receiving infliximab

Location: MR201

Presenting Author: – ETH Zurich

1:45 PM – 2:00 PM ADT

A pilot evaluation of switchback from biosimilars to originator-biologics in the Veterans Affairs population: a signal of biosimilar failure?

Location: MR201

Presenting Author: – Veterans Affairs Center for Medication Safety, Department of Veterans Affairs

2:00 PM – 2:15 PM ADT

Decreased Discontinuation and Switching of b/tsDMARDs in RA When Treatment Aligns with Molecular Signature Response Classifier Results: An Analysis from The Study to Accelerate Information of Molecular Signatures (AIMS)

Location: MR201

Presenting Author: – University of Alabama at Birmingham

2:15 PM – 2:30 PM ADT

Trends in Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among Commercially Insured Adults and Children in the United States, 2001-2020

Location: MR201

Presenting Author: – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ

2:30 PM – 2:45 PM ADT

Integration of Immuno-oncology (IO) Treatments into Routine Clinical Practice for the Treatment of Patients with Advanced or Metastatic Cancers: Analysis of the England National Cancer Registry

Location: MR201

Presenting Author: – Global Epidemiology, the healthcare business of Merck KGaA, Darmstadt, Germany

2:45 PM – 3:00 PM ADT

The use of denosumab and the risk of incidence of diabetes in patients with osteoporosis

Location: MR201

Presenting Author: – Institute of Clinical Pharmacy and Pharmaceutical Sciences (CPPS), College of Medicine, National Cheng Kung University, Tainan, Taiwan.

1:30 PM – 3:00 PM ADT

What Can Be Learned From Machines

Location: MR202

Co-Moderator: – Aetion

Co-Moderator: – Department of Medical Informatics, Erasmus MC University

1:30 PM – 1:45 PM ADT

Opportunities and challenges surrounding the incorporation of laboratory test-result information within high-dimensional confounder adjustment procedures

Location: MR202

Presenting Author: – London School of Hygiene and Tropical Medicine

1:45 PM – 2:00 PM ADT

Comparison of Stable Balancing Weights vs Propensity Score Weighting for RWE or External Clinical Study Comparison Arms to Single Arm Clinical Trials

Location: MR202

Presenting Author: – Johnson & Johnson

2:00 PM – 2:15 PM ADT

Standardization over disease risk score versus propensity score for confounding control when using random forests for model fitting

Location: MR202

Presenting Author: – Department of Epidemiology, Biostatistics and Occupational Health, McGill University

2:15 PM – 2:30 PM ADT

High-dimensional Iterative Causal Forest (hdiCF): a Novel Algorithm for Subgroup Identification in Claims Data

Location: MR202

Presenting Author: – University of North Carolina at Chapel Hill, Department of Epidemiology

2:30 PM – 2:45 PM ADT

Can Machine Learning approaches help accelerating rare diseases diagnosis? The Acromegaly Case Study

Location: MR202

Presenting Author: – Department of Medicine, University of Verona, Verona, Italy

2:45 PM – 3:00 PM ADT

Severity Score Extraction from Clinical Notes Using Natural Language Processing: Applications to Dermatology

Location: MR202

Presenting Author: – OMNY Health

3:00 PM – 3:15 PM ADT

Break

3:15 PM – 4:45 PM ADT

Hot Topic Session: Health Equity and Diversity in Pharmacoepidemiology Research: Making Change Happen

Location: Ballroom

Introducer/Moderator: – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands

Speaker: – University of Maryland School of Public Health

Speaker: – University of California San Francisco

Speaker: – Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen

4:45 PM – 5:30 PM ADT

The Final Word

Location: Ballroom